- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06738368
Etopósido, prednisona, vincristina, ciclofosfamida y doxorrubicina (DA-EPOCH) con o sin rituximab más Erwinia asparaginasa recombinante (JZP458) para el tratamiento de la leucemia linfoblástica aguda B con pH negativo o la leucemia linfoblástica aguda T recién diagnosticada
Etopósido, prednisona, vincristina, ciclofosfamida y doxorrubicina de dosis ajustada (DA-EPOCH) ± rituximab + Erwinia asparaginasa recombinante (JZP458; Rylaze®) para el tratamiento de adultos recién diagnosticados con leucemia o linfoma linfoblástico agudo con cromosoma Filadelfia negativo
This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly diagnosed Philadelphia chromosome (Ph) negative B-acute lymphoblastic leukemia (ALL) or T-ALL. Chemotherapy drugs, such as etoposide, vincristine, cyclophosphamide and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. JZP458 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving DA-EPOCH with or without rituximab plus JZP458 may kill more cancer cells in patients with newly diagnosed Ph negative B-ALL or T-ALL.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
- Droga: Cyclophosphamide
- Droga: Prednisone
- Procedimiento: Biospecimen Collection
- Biológico: Rituximab
- Procedimiento: Computed Tomography
- Procedimiento: Positron Emission Tomography
- Biológico: Filgrastim
- Biológico: Pegfilgrastim
- Droga: Asparaginase Erwinia chrysanthemi
- Procedimiento: Bone Marrow Collection
- Droga: Doxorubicin
- Droga: Etoposide
- Droga: Vincristine
Descripción detallada
OUTLINE:
Patients receive etoposide intravenously (IV), doxorubicin IV and vincristine IV over 96 hours on days 1-4, cyclophosphamide IV over 1 hour on day 5, prednisone orally (PO) twice daily (BID) on days 1-5 of each cycle. In addition, CD20 positive patients receive rituximab IV on day 1 or 5 of each cycle. Patients also receive JZP458 intramuscularly (IM) once every 2-3 days on days 7-21 for up to 7 doses. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 6, 7, or 8, patients also receive pegfilgrastim subcutaneously (SC) once or filgrastim SC once daily (QD) until absolute neutrophil count (ANC) > 2000/uL past nadir. Patients also undergo blood sample collection and bone marrow collection throughout the study. Additionally, patients with extramedullary disease may undergo computed tomography (CT) or positron emission tomography (PET)/CT throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years then every 6 months for up to 3 years.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults (age 18 years and older) with newly-diagnosed Ph- B-ALL or T-ALL
- In the opinion of the treating investigator, patients must be an unsuitable candidate for a pediatric-inspired regimen, reasons for which may include (but not be limited to) older age (e.g., ≥ 40 years), practical/logistical barriers to or toxicity concerns from administration of a pediatric-inspired regimen
- Marrow or blood involvement by ALL detectable by multi-parameter flow cytometry (MFC)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. (Performance status of 3 will be allowed if poor performance status is thought to be directly secondary to ALL.)
- Total bilirubin ≤ 2.0 x upper limit of normal (ULN) (unless attributed to Gilbert's disease or other causes of inherited indirect hyperbilirubinemia, at which point total bilirubin must be ≤ 4.0 x ULN) (Note: Patients with liver test abnormalities attributable to hepatic involvement by ALL will be permitted if the total bilirubin is ≤ 5.0 x ULN and alanine aminotransferase [ALT]/aspartate aminotransferase [AST] are ≤ 8.0 x ULN.)
- AST (serum glutamic oxaloacetic transaminase [SGOT])/ALT (serum glutamic pyruvic transaminase [SGPT]) ≤ 5.0 x institutional ULN. (Note: Patients with liver test abnormalities attributable to hepatic involvement by ALL will be permitted if the total bilirubin is ≤ 5.0 x ULN and ALT/AST are ≤ 8.0 x ULN.)
- Calculated creatinine clearance of ≥ 60 ml/min/1.73 m^2, as measured by the Modification of Diet in Renal Disease (MDRD) equation, will be eligible
- As patients with ALL frequently have cytopenias, no hematologic parameters will be required for enrollment or to receive the first cycle of treatment. However, adequate recovery of blood counts will be required to receive subsequent cycles
- Ability to give informed consent and comply with the protocol
- Anticipated survival of at least 3 months, independent of ALL
- Female subjects of childbearing potential should use effective non-hormonal contraceptive methods during treatment with JZP458 and for 3 months after the last dose of study drug. Male subjects with female partners of childbearing potential must agree to use an effective method of birth control from the time of signing the consent form until at least 3 months after the last dose of study drug
Exclusion Criteria:
-
Prior systemic therapy for ALL except to control acute symptoms and/or leukocytosis (e.g., corticosteroids, cytarabine, etc.). Cytarabine 500 mg/m^2 per dose up to 2 doses and/or the equivalent of prednisone 50 mg/m^2/day for up to 2 days are permitted
-
Burkitt lymphoma/leukemia
-
Isolated extramedullary or known parenchymal central nervous system (CNS) disease
-
Known hypersensitivity or intolerance to any of the agents under investigation
-
Known history of grade 3+ pancreatitis or chronic pancreatic insufficiency
-
Known active chronic liver disease including, but not limited to, non-alcoholic steatohepatitis, cirrhosis, or non-alcoholic fatty liver disease
-
Other medical or psychiatric conditions that in the opinion of the investigator would preclude safe participation in the protocol
-
Pregnant or nursing
- Pregnancy test is only required in women, unless they are highly unlikely to conceive (defined as [1] surgically sterilized, or [2] postmenopausal [i.e., a woman who is > 50 years old or who has not had menses for ≥ 1 year], or [3] not heterosexually active)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Treatment (DA-EPOCH, rituximab, JZP458)
Patients receive etoposide IV, doxorubicin IV and vincristine IV over 96 hours on days 1-4, cyclophosphamide IV over 1 hour on day 5, prednisone PO BID on days 1-5 of each cycle. In addition, CD20 positive patients receive rituximab IV on day 1 or 5 of each cycle. Patients also receive JZP458 IM every 2-3 days on days 7-21 for up to 7 doses. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 6, 7, or 8, patients also receive pegfilgrastim SC once or filgrastim SC QD until ANC > 2000/uL past nadir. Patients also undergo blood sample collection and bone marrow collection throughout the study. Additionally, patients with extramedullary disease may undergo CT or PET/CT throughout the study. |
Given IV
Otros nombres:
Given PO
Otros nombres:
Undergo blood sample collection
Otros nombres:
Given IV
Otros nombres:
Undergo CT or PET/CT
Otros nombres:
Undergo PET/CT
Otros nombres:
Given SC
Otros nombres:
Given SC
Otros nombres:
Given IM
Otros nombres:
Undergo bone marrow sample collection
Otros nombres:
Given CIV
Otros nombres:
Given CIV
Otros nombres:
Given CIV
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Measurable residual disease (MRD) negativity
Periodo de tiempo: After 4 cycles of treatment (cycle length = 21 days)
|
Will be measured by multi-parameter flow cytometry (MFC). Will be assessed according to the National Comprehensive Cancer Network response criteria. |
After 4 cycles of treatment (cycle length = 21 days)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
MRD negativity
Periodo de tiempo: After 1 cycle of study therapy (cycle length = 21 days)
|
Will be measured by MFC. Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. |
After 1 cycle of study therapy (cycle length = 21 days)
|
|
Incidence of grade 3 or higher non-hematologic adverse events (AEs)
Periodo de tiempo: Up to 30 days after last dose of study treatment
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. The incidence of AEs will be reported as ratios or percentages. |
Up to 30 days after last dose of study treatment
|
|
Event-free survival (EFS)
Periodo de tiempo: Up to 5 years
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. Kaplan-Meier curves will be used to depict EFS. |
Up to 5 years
|
|
Relapse-free survival (RFS)
Periodo de tiempo: Up to 5 years
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. Kaplan-Meier curves will be used to depict RFS. |
Up to 5 years
|
|
Overall survival (OS)
Periodo de tiempo: Up to 5 years
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. Kaplan-Meier curves will be used to depict OS. |
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Ryan D. Cassaday, MD, Fred Hutch/University of Washington Cancer Consortium
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias
- Enfermedades del sistema inmunológico
- Infecciones
- Enfermedades virales
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Infecciones por virus de ADN
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Linfoma de células B
- Linfoma
- Leucemia Linfoide
- Leucemia
- Infecciones por el virus de Epstein-Barr
- Infecciones por herpesviridae
- Infecciones por virus tumorales
- Leucemia-linfoma linfoblástico de células precursoras
- Enfermedades hemic y linfáticas
- Linfoma de Burkitt
- Leucemia-linfoma linfoblástico de células T precursoras
- Péptidos
- Aminoácidos, péptidos y proteínas
- Proteínas
- Químicos orgánicos
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Técnicas de investigación
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Hidrocarburos
- Hidrocarburos, cíclico
- Factores biológicos
- Carbohidratos
- Alcaloides
- Podoflotoxina
- Tetrahidronaftalenos
- Naftalenos
- Hidrocarburos aromáticos policíclicos
- Hidrocarburos, aromáticos
- Compuestos policíclicos
- Glucósidos
- Glucósidos
- Hidrolasas
- Enzimas
- Enzimas y coenzimas
- Indoles
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Espierra
- Embarazos
- Esteroides
- Compuestos de anillo fusionado
- Técnicas de química, analítica
- Análisis de espectro
- Mostaza de fosforamida
- Compuestos de mostaza de nitrógeno
- Compuestos de mostaza
- Hidrocarburos, halogenados
- Fosforamidas
- Compuestos organofosforados
- Péptidos de señalización intercelular y proteínas
- Madreadiediols
- Amidohidrolasas
- Alcaloides de Vinca
- Alcaloides de triptamina de secologanina
- Alcaloides de indol
- Indolizidinas
- Indolizinas
- Antraciclinas
- Naftacenos
- Aminoglucósidos
- Glicoproteínas
- Glucoconjugados
- Anticuerpos, monoclonales, derivados de murino
- Daunorrubicina
- Factores estimulantes de colonias
- Factores de crecimiento de células hematopoyéticas
- Citocinas
- Rituximab
- Prednisona
- Ciclofosfamida
- Etopósido
- Doxorrubicina
- Vincristina
- Asparaginasa
- Manejo de muestras
- Espectroscopía de resonancia magnética
- CT-P10
- Factor estimulador de colonias de granulocitos
- Filgrastim
- deltacorteno
- predilideno
- pegfilgrastim
- asparaginasa erwinia crysanthemi recombinante
- Factor estimulante de colonias de granulocitos de PEGLADA
Otros números de identificación del estudio
- RG1124788
- NCI-2024-09417 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- FHIRB0020869 (Otro identificador: Fred Hutch/University of Washington Cancer Consortium)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .